# INTERCEPTA v3.0 — FINAL RECONSTRUCTED BUILD GUIDE
## PART 5 OF 6: PHASE 6 — PHARMA MVP (Weeks 35-42)
## PART 6 OF 6: ALL PARALLEL TRACKS (Continuous)
### Version: FINAL — Complete Commercial Platform + Funding + IP + Team

**Status: COMPLETE — Report generator + all business strategy**

---

# PHASE 6: PHARMA MVP

## FILE: `src/module7_output/report_generator.py`

**Contains:** ReportGenerator class with:
- `generate_pharma_report()` — Full combination discovery report
- `_build_executive_summary()` — Headline + key finding
- `_build_resistance_section()` — Resistant fraction + mechanism + interpretation
- `_build_top4_section()` — Rank, drugs, efficacy, toxicity, mechanism, recommendation per combo
- `_build_novelty_section()` — Novel combinations identified (uses NoveltyChecker)
- `_build_pareto_section()` — Trade-off analysis
- `_build_confidence_section()` — Limitations + honest uncertainty disclosure
- `_build_methods_section()` — Pipeline description + key references
- `_generate_html_report()` — Full interactive HTML with CSS styling
- `_explain_mechanism()` — Auto-generates mechanistic explanation from drug library
- `_generate_recommendation()` — Rank-specific clinical recommendation text
- `_interpret_resistance()` — Translates resistance mechanism to clinical language

**Output formats:**
- JSON (machine-readable, for API integration)
- HTML (interactive, for human review)
- Both saved to outputs/reports/

All code delivered in Part 6 original — no changes needed (this module had no gaps).

---

# ALL PARALLEL TRACKS

## TRACK A: FUNDING STRATEGY

### Month 1-2: NIH SBIR Phase I ($275K / 6 months)
```
Title: "INTERCEPTA: Exhaustive Computational Drug Combination 
       Screening for Precision Oncology in Metastatic Prostate Cancer"
Aims:
  1. Validate resistance detection (>80% concordance)
  2. Validate drug sensitivity (AUROC >0.75)
  3. Retrospective validation (recover known trial outcomes)
```

### Month 3-6: Accelerator Applications
- IndieBio ($250K, biotech-focused)
- Y Combinator ($500K, broad)
- Creative Destruction Lab (computational biology track)
- Petri ($150-250K, biotech)

### Month 6-12: DOD Prostate Cancer Research Program ($200-400K / 2 years)

### Month 12-18: Seed Round ($1-2M, if validation strong)

## TRACK B: IP PROTECTION

### Provisional Patent Filing (BEFORE any publication, target Week 25)

**4 Claims:**
1. Integrated pipeline: domain adaptation + exhaustive screening
2. Triple-layer resistance detection: signatures + fate mapping + velocity consensus
3. Tiered input architecture: scRNA-seq / bulk / genomics-only
4. Hybrid IDA-synergy scoring: IDA baseline + clinical-trial-derived corrections

**Budget:** $3,000-5,000 for provisional (12-month protection)

## TRACK C: TEAM RECRUITMENT

### Clinical Oncology Advisor (Month 1-3, 0.5-1% equity + $500/mo)
Target: GU oncologists at academic centers with scRNA-seq programs
Outreach: Authors of PNAS 2024 prostate scRNA-seq paper, SU2C/PCF network

### Pharmacometrics Advisor (Month 6, consulting + equity)
Target: PK/PD modelers from pharma or ISOP network

### Regulatory Advisor (Month 12, consulting fee)
Target: Former FDA SaMD reviewers

## TRACK D: CLINICAL PARTNERSHIPS

### Stage 1 (Month 6-12): Data sharing agreements with academic centers
### Stage 2 (Month 12-18): Retrospective validation study (N=50-100)
### Stage 3 (Month 24+): Prospective pilot (N=20-50)

## TRACK E: PHARMA OUTREACH (After paper submitted, Month 12+)

**Target companies:** AstraZeneca (olaparib), Pfizer/Astellas (enzalutamide),
Janssen (abiraterone), Merck (pembrolizumab), Bayer (darolutamide), Novartis (radioligand)

**Entry:** Scientific conferences (ASCO GU, AACR, ESMO)
**Strategy:** Free pilot analysis → paid service ($300-500K per engagement)

---

# COMPLETE PROJECT TIMELINE

```
MONTH:  1    2    3    4    5    6    7    8    9   10   11   12   15   18   24
        |    |    |    |    |    |    |    |    |    |    |    |    |    |    |
PH 0:   ████                                                    Foundation
PH 1:        █████████████                                       Resistance
PH 2:                      ████████████                          Sensitivity
PH 3:                                    ██████████              Model+Score
PH 4:                                              ████         Integration
PH 5:                                                   ████████ Paper
PH 6:                                                            ████████ MVP

FUND:   ████████████████████████████████████████████████████████████████████
        SBIR     Accelerators    DOD                        Seed round

IP:                                      ██                      Patent
TEAM:   ████████████                                             Advisor
PARTN:                     ████████████████████████████████████████████████
                          Data sharing    Retrospective    Pharma outreach
```

**Milestones:**
- M1 (Month 3): Resistance validated >80% concordance
- M2 (Month 5): Drug sensitivity AUROC >0.75
- M3 (Month 7): Model reproduces LATITUDE + PROfound
- M4 (Month 9): End-to-end pipeline working
- M5 (Month 12): Validation paper submitted
- M6 (Month 15): First pharma engagement

---

*PARTS 5-6 RECONSTRUCTION COMPLETE.*
*Contains: Report generator (Module 7), complete funding strategy,*
*IP claims, team recruitment plan, clinical partnership pathway,*
*pharma outreach strategy, full project timeline.*
